Form 4: Aurinia Pharmaceuticals Director Acquires Stock Options

Aurinia Pharmaceuticals Inc. Director Craig A. Johnson acquired 23,931 stock options with an exercise price of $15.67, vesting one year from the grant date.

Summary

• Director Craig A. Johnson of Aurinia Pharmaceuticals Inc. acquired 23,931 stock options.
• The options have an exercise price of $15.67 per share.
• These options are exercisable and will vest one year from the grant date, which is June 4, 2026.
• The underlying securities are common shares.
• This transaction was reported on June 8, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard stock option grant to a director rather than a significant new investment or divestment.

Positives

• Director's acquisition of stock options signals confidence in the company's future prospects.
• The options are exercisable, providing potential future equity ownership for the director.

Future Outlook

The vesting of options one year from the grant date suggests a medium-term outlook for the director's potential equity realization, contingent on continued service and company performance.

Industry Context

StockSavvy.ai notes that director stock option grants are a common form of executive compensation in the biopharmaceutical industry, aligning management interests with shareholder value.

Stakeholder Impact

• Shareholders: The grant of options to a director can be viewed positively as it aligns director incentives with company performance and share price appreciation.

Next Steps

• The options will vest one year from the grant date (June 4, 2026).

Key Dates

Keywords

Aurinia Pharmaceuticals, AUPH, Form 4, Stock Options, Director, Beneficial Ownership, SEC Filing, Equity